Relapsed and refractory multiple myeloma (RRMM), multiple myeloma (MM) with progression within 18 months of initial treatment/ or newly diagnosed multiple myeloma (NDMM) with suboptimal response post autologous stem cell transplant (ASCT) (Cohort 3 only)
Conditions
Brief summary
Overall response rate (ORR) (Cohort 1), Complete response (CR) rate Cohort 1b,Cohort2a,Cohort 2b,Cohort 2c,and Cohort 3
Detailed description
Complete response (CR) rate (Cohort 1), Overall response rate (ORR) Cohort 1b, 2a, b,cand Cohort 3, Very good partial response (VGPR) rate (Cohort 2c), Time to response (TTR), Duration of response (DoR), Progression-free survival (PFS), Time to progression (TTP), Overall survival (OS), Pharmacokinetics, Immunogenicity, Health-related Quality of Life (HRQoL), Feasibility of lenalidomide maintenance therapy post-bb2121 infusion (Cohort 3)
Interventions
Sponsors
Celgene Corp.
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall response rate (ORR) (Cohort 1), Complete response (CR) rate Cohort 1b,Cohort2a,Cohort 2b,Cohort 2c,and Cohort 3 | — |
Secondary
| Measure | Time frame |
|---|---|
| Complete response (CR) rate (Cohort 1), Overall response rate (ORR) Cohort 1b, 2a, b,cand Cohort 3, Very good partial response (VGPR) rate (Cohort 2c), Time to response (TTR), Duration of response (DoR), Progression-free survival (PFS), Time to progression (TTP), Overall survival (OS), Pharmacokinetics, Immunogenicity, Health-related Quality of Life (HRQoL), Feasibility of lenalidomide maintenance therapy post-bb2121 infusion (Cohort 3) | — |
Countries
France, Germany, Spain
Outcome results
None listed